It would also be interesting to see if PD-L1 expression can enrich for clinical benefit in HER2-positive gastric cancers, similar to what we have observed in HER2-negative patients where chemo-immunotherapy is already a standard-of-care for treatment-naive patients with a PD-L1 Combined Positive Score of ≥5. Here, ERBB2 is linked to gastric cancer.